Fortis Healthcare Limited (FORTIS) Fair Value & Analysis
Healthcare · IN · Market cap ₹727B
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 23 days ago
Fair value updated Jul 18, 2026, revised from ₹303.58 to ₹546.44 (+80.0%) since Jul 16, 2026. Share price +1.2% over the past month.
A solid business, but screening 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹683.06). The favourable scenario is already priced in.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (₹282.89 to ₹683.06) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 18, 2026.
How to read this chart
60‑month range ₹199.15 – ₹1,098 · fair‑value band ₹282.89 – ₹683.06 · the ₹955.15 price screens above the ₹546.44 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 18, 2026.
Analysis
Fortis Healthcare Limited (FORTIS) currently trades at ₹955.15, while our model-based Fair Value estimate is ₹546.44, implying the stock looks roughly 42.8% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Fortis Healthcare Limited generated revenue of ₹91.3B at a net margin of 11.4%. Revenue grew 17.8% year over year. It earns a return on equity of 11.0%. Net debt stands at ₹29.3B. Fundamentals as of Jul 18, 2026
Our scenario range runs from ₹282.89 (bear case) to ₹683.06 (bull case); at ₹955.15, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 14% below its 52-week high and 29% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -43%, FORTIS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (₹336.07) versus Dividend Discount (₹17.70). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 60
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, …
Full company description
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company offers services in the areas of cardiac science, critical care, vascular surgery, dental science, dermatology, diabetology/endocrinology, emergency and trauma, geriatric medicine, liver transplant and hepatobiliary sciences, pain and palliative medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, and haematology areas. It also provides services in the areas of infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, organ transplant, rheumatology, thoracic surgery, transfusion medicine, urology, medical generics, endocrine surgery, and other support specialties, as well as treat infectious diseases. The company's healthcare verticals comprise hospitals, diagnostics, tertiary and quaternary care, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Fortis Healthcare Limited reported revenue of ₹91.3B in FY2026 versus ₹57.2B in FY2022, a compound +12.4%/yr. Reported net income was ₹10.4B in FY2026, compounding +17.0%/yr from FY2022.
FORTIS screens 43% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 262 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Fortis Healthcare Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Fortis Healthcare Limited (FORTIS) overvalued or undervalued?
What is the fair value of FORTIS?
What is the quality score of FORTIS?
What is the revenue of Fortis Healthcare Limited (FORTIS)?
What is the net profit margin of FORTIS?
Does Fortis Healthcare Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Fortis Healthcare Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.